07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

Aurigene, Curis deal

Curis exercised an option from Aurigene to license exclusive, worldwide rights outside India and Russia to preclinical oncology candidate CA-327 -- an oral small molecule antagonist of PD-L1 and T cell immunoglobulin and mucin domain...